Discontinuations and Withdrawal [Design Issues]

posted by kvgreddy06 – India, 2013-10-09 15:09 (4643 d 15:15 ago) – Posting: # 11631
Views: 4,734

Hello All

If a drug contain combination of two formulations [IR+ CR] for that drug how can justify the Discontinuation and Withdrawal criteria in case of emesis?

Generally as per guidelines

For IR fomulations we go through as subject experiences emesis within twice the median tmax of X drug after administration of IP.

For CR formulations: subject experiences emesis any time within the labelled dosing interval of the IP


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
408 visitors (0 registered, 408 guests [including 19 identified bots]).
Forum time: 06:24 CEST (Europe/Vienna)

Don’t compromise yourself.
You are all you’ve got.    Janis Joplin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5